Pharmaceutical - Financial, Johnson & Johnson

Filter

Popular Filters

1 to 25 of 34 results

Johnson & Johnson 1st-qtr 2014 results beat expectations

Johnson & Johnson 1st-qtr 2014 results beat expectations

15-04-2014

US health care giant Johnson & Johnson today reported financial results for the first quarter of 2014,…

FinancialJohnson & JohnsonPharmaceutical

Johnson & Johnson beats expectations, as earnings jump 37%

Johnson & Johnson beats expectations, as earnings jump 37%

22-01-2014

US health care giant Johnson & Johnson reported fourth-quarter and full-year 2013 financials, showing…

FinancialJohnson & JohnsonPharmaceutical

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

11-12-2013

The European Commission has imposed fines of 10.8 million euros ($14.8 million) on the US health care…

EuropefentanylFinancialJohnson & JohnsonNeurologicalNovartisPatentsPharmaceuticalSandoz

J&J unit DePuy in $2.5 billion US settlement relating to ASR Hip System

20-11-2013

US health care giant Johnson & Johnson’s subsidiary DePuy Orthopaedics and the Court-appointed committee…

DePuyFinancialJohnson & JohnsonLegalNorth AmericaPharmaceutical

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms

19-11-2013

Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

Johnson & Johnson to pay over $2.2 billion to settle DoJ probe

Johnson & Johnson to pay over $2.2 billion to settle DoJ probe

05-11-2013

Global health care giant Johnson & Johnson and its subsidiaries will pay more than $2.2 billion to resolve…

FinancialInvegaJanssenJohnson & JohnsonLegalMarkets & MarketingNatrecorNorth AmericaPharmaceuticalRisperdalScios

Johnson & Johnson third quarter beats analysts’ forecasts boosted by new Rx drugs

Johnson & Johnson third quarter beats analysts’ forecasts boosted by new Rx drugs

16-10-2013

Johnson & Johnson kicked off the third-quarter 2013 pharma financial results reporting period, posting…

FinancialJohnson & JohnsonPharmaceutical

Johnson & Johnson 2nd-qtr beats expectations

17-07-2013

US health care giant Johnson & Johnson (NYSE: JNJ) reported second quarter 2013 earnings of $3.83 billion,…

FinancialJohnson & JohnsonPharmaceutical

Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

24-05-2013

At a meeting today with industry analysts, senior leaders from the Janssen pharmaceutical companies of…

FinancialJanssenJohnson & JohnsonPharmaceuticalRegulationResearch

Johnson & Johnson beats forecasts, despite 11% profit decline

17-04-2013

Johnson & Johnson (NYSE: JNJ), the first of the US health care majors to report first-quarter 2013 financial…

FinancialJohnson & JohnsonPharmaceutical

Australia to subsidize groundbreaking hepatitis C drugs under PBS

19-02-2013

The Australian government said on February 19 that it is extended subsidies of important medicines each…

Anti-viralsAsia-PacificFinancialHealthcareIncivoJohnson & JohnsonMerck & CoPharmaceuticalPricingVictrelis

Johnson & Johnson 4th-qtr sales miss expectations and guidance disappoints

23-01-2013

US health care giant Johnson & Johnson (NYSE: JNJ) yesterday posted fourth-quarter and full-year 2012…

FinancialJohnson & JohnsonPharmaceutical

Johnson & Johnson beats expectations, despite 7% 3rd-qtr profit fall

17-10-2012

US health care giant Johnson & Johnson (NYSE: JNJ) yesterday revealed that its third-quarter 2012 profit…

FinancialJohnson & JohnsonPharmaceutical

Genmab leaps on $1.1 billion daratumumab deal with Janssen

31-08-2012

Denmark's Genmab A/S (OMX: GEN) saw its shares leap 20% to 81 Danish kroner in morning trading yesterday,…

BiotechnologydaratumumabFinancialGenmabHuMax-CD38JanssenJohnson & JohnsonLicensingOncologyPharmaceutical

Pharmacyclics gets second $50 million milestone from Janssen

21-08-2012

California, USA-based Pharmacyclics (Nasdaq: PCYC) announced yesterday that the SPARK (MCL2001) clinical…

BiotechnologyFinancialibrutinibJanssenJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Johnson & Johnson close to settling over Risperdal marketing; SEC probes Teva

06-08-2012

US health care giant Johnson & Johnson (NYSE: JNJ) has reached "an agreement in principle'' with the…

FinancialGenericsInvegaJanssenJohnson & JohnsonLegalMarkets & MarketingNatrecorNorth AmericaPharmaceuticalRisperdalTeva Pharmaceutical Industries

Pharmacyclics gets $50 milestone from J&J on ibrutinib progress

03-08-2012

California, USA-based Pharmacyclics (Nasdaq: PCYC) says it that enrolment of the fifth patient in the…

FinancialibrutinibJanssenJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Johnson & Johnson 2nd-qtr earnings slump on charges and currencies

18-07-2012

US health care giant Johnson & Johnson (NYSE: JNJ) yesterday announced second-quarter 2012 financial…

FinancialJohnson & JohnsonPharmaceutical

UK academia-pharma collaboration attracts £14.4 million funding

13-05-2012

In the UK, the University of Dundee and the Medical Research Council (MRC) have announced new funding…

AstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck SeronoPfizerPharmaceuticalResearch

Johnson & Johnson 1st-qtr earnings up 12.5% but sales flat

18-04-2012

US health care giant Johnson & Johnson (NYSE: JNJ) posted first-quarter 2012 financial results in line…

FinancialJohnson & JohnsonPharmaceutical

News briefs on Janssen, Bayer and Merck KGaA/Threshold

12-04-2012

In the USA, the Arkansas jury found that the Janssen unit of US health care giant Johnson & Johnson (NYSE:…

BayerFinancialJanssenJohnson & JohnsonLegalMerck KGaAPharmaceuticalRegulationRisperdalThreshold PharmaceuticalsXarelto

1 to 25 of 34 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top